Johnson & Johnson (NYSE:JNJ) has been one of the most consistent and successful companies on earth. It is a company that is truly global in scale, and it is so profitable and diverse that it controls its own destiny. As global populations continue to grow and age, Johnson & Johnson will thrive for decades more. The stock has historically never been truly cheap, and it likely never will be as investors recognize the value in top-tier companies and price them accordingly. Going forward, Johnson & Johnson is very likely to continue to generate huge cash flows and will most certainly allocate these cash flows into higher dividends, more R&D, and more earnings accretive acquisitions such as the pending purchase of Switzerland's Actelion (OTCPK:ALIOY). Conservative investors would be wise to accumulate shares during this current period of consolidation knowing that history tells us it won't last much longer.
